Summary

  • Gilead's strongest public evidence is not a marketing claim. Its latest Form 10-K and Q1 2026 Form 10-Q show a company whose economics are still dominated by HIV treatment and prevention: 2025 HIV product sales were $20.8 billion, Biktarvy alone was $14.3 billion, Q1 2026 HIV sales rose 10% year over year, and Yeztugo already contributed $166 million in its first reported quarter.
  • The treatment-course argument is strong but not complete. The FDA label for Yeztugo supports a differentiated twice-yearly prevention course with compelling trial results, while Gilead's filings show 41% gross-to-net deductions, Medicare redesign pressure, Florida ADAP restrictions on Biktarvy and Descovy, and a 2030s patent calendar that forces each course to prove value before policy and generic pressure compress realized price.

For a payer, the first question about Gilead is not whether the company is important. It is. The harder question is whether a course of therapy deserves the access contract it asks the health system to support. That contract may be a daily HIV treatment tablet, a prevention medicine taken daily or injected every six months, a hepatitis treatment, a hospital antiviral, or a cell therapy assembled through a chain of certified sites. In each case, the buyer is paying for a clinical outcome, regulatory evidence, manufacturing reliability, distribution reach, patient support and patent-protected scarcity. The same buyer also knows that the bill will be challenged by government budgets, pharmacy-benefit managers, public programs, generic applicants, rival branded drugs and the practical limits of clinic capacity.

That is why Gilead Sciences, Inc. is best read through the unit the assignment sets: the treatment course and access contract. The medicine may be packaged as tablets, vials or a kit. The economic unit is the completed course that a patient can actually receive, remain on, and benefit from, with the payer accepting the price and the provider able to manage the safety and adherence obligations. In HIV, that unit is especially visible. A Biktarvy course is a daily treatment regimen that protects a large revenue base so long as patients and clinicians prefer it to other regimens and payers accept the net cost. A Descovy for PrEP course is a prevention option competing against generic tenofovir disoproxil fumarate/emtricitabine and other PrEP choices. A Yeztugo course is a scheduled long-acting prevention course: the label requires initiation dosing, two subcutaneous injections every six months after that, and HIV testing before initiation and before each subsequent injection.

The hard anchor is Gilead's own audited record. In its 2025 Form 10-K, filed with the US Securities and Exchange Commission on February 24, 2026, Gilead reported total 2025 revenue of $29.443 billion and total product sales of $28.915 billion. HIV product sales were $20.752 billion, or roughly 72% of product sales. Biktarvy alone produced $14.334 billion of 2025 sales, up 7% from 2024. Descovy produced $2.758 billion, up 31%. The company also disclosed gross-to-net deductions of $19.953 billion, equal to 41% of gross product sales, including $17.5 billion of rebates and chargebacks. In Q1 2026, the most recent quarterly filing available before this article date, Gilead reported $6.960 billion of total revenue, $6.946 billion of product sales, HIV product sales of $5.030 billion, Biktarvy sales of $3.361 billion, Descovy sales of $807 million and Yeztugo sales of $166 million.

Those figures establish the problem. Gilead's economic engine is not simply scientific prestige. It is a net-price machine built around a small number of protected courses, with HIV providing the largest recurring cash flow. The company can spend $5.8 billion on research and development in 2025, absorb $1.0 billion of acquired in-process research and development expense, pay interest on a large debt stack, invest in manufacturing and still report a 78.4% product gross margin because enough treatment courses clear enough reimbursement hurdles at high enough net prices. The model works when outcomes, convenience, safety, patent protection and payer coverage reinforce each other. It weakens when any one of those conditions breaks.

Gilead's identity is straightforward. The SEC submission record lists Gilead Sciences, Inc. as a Delaware corporation with common stock traded on Nasdaq under the ticker GILD, headquartered at 333 Lakeside Drive, Foster City, California 94404. The same SEC record classifies it in biological products and lists the issuer as a large accelerated filer. The company's own annual report describes a commercial biopharmaceutical business focused on virology, oncology and inflammation, with US and international commercial sales operations, marketing subsidiaries in more than 35 countries, and products promoted through direct field contact with physicians, hospitals, clinics and other healthcare providers. It sells most US products through the wholesale channel; historically about 90% of US gross product sales have gone through Cardinal Health, Cencora and McKesson and their specialty distributor affiliates.

This is a public company, not a subsidiary operating under a visible parent. Its ownership context is public-market ownership through listed equity, with board and management accountability through securities filings. That matters because the treatment-course thesis is visible in reported numbers. Gilead does not need a single payer to write one giant contract. It needs thousands of payers, public programs, wholesalers, clinics and prescribers to keep accepting a portfolio of courses whose value claims differ by disease. The HIV franchise is the cleanest case because treatment and prevention are long-duration, access-sensitive and exposed to public health budgets.

The buyer of a Gilead course varies. A patient may be the person taking the tablet or receiving the injection, but the practical payer is usually a private insurer, Medicare Part D plan, Medicaid agency, AIDS Drug Assistance Program, Veterans Affairs facility, correctional health system, national health system, hospital, integrated health plan, or another institutional purchaser. A specialty pharmacy, wholesaler or clinic may sit in the channel, but it is not the final economic judge. The judge is the payer deciding whether the course earns placement, prior authorization, rebate acceptance, provider reimbursement and patient affordability. In that decision, clinical evidence is necessary but not sufficient.

Biktarvy shows the mature-course side of the business. It combines bictegravir, emtricitabine and tenofovir alafenamide in a daily single-tablet regimen for HIV treatment. Gilead's annual report says Biktarvy sales increased in 2025 because of higher demand, including patients switching from Genvoya and other Gilead HIV products, partly offset by lower average realized price due to the US Medicare Part D program redesign. In Q1 2026, Biktarvy sales again rose, this time with Gilead citing higher demand and average realized price, partly offset by unfavorable inventory dynamics. The public record therefore supports a course with real switching power and large installed demand, but also shows it is not insulated from policy redesign and channel timing.

Descovy shows the prevention and substitution problem. The annual report attributes the 2025 increase to higher demand and average realized price. The Q1 2026 filing says Descovy sales rose 38%, primarily from higher average realized price and demand. But Descovy is exposed to two kinds of pressure. First, PrEP alternatives include generic Truvada-equivalent products, which give payers a cheap substitute for many patients even if not every patient is clinically interchangeable. Second, Gilead disclosed in the Q1 2026 filing that Florida ADAP implemented cost-containment measures in March 2026, including removing Biktarvy from the formulary and imposing additional restrictions on access to Descovy. That single public-program example does not prove a national trend by itself, but it is exactly the kind of official payer action that tests whether a course can keep access when budgets tighten.

Yeztugo is the newest test of the course thesis. The DailyMed label, with the current set published February 17, 2026, identifies Yeztugo as lenacapavir for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kilograms who are at risk of HIV-1 acquisition. The dosing schedule is not a casual convenience claim. The label requires initiation with 927 mg by subcutaneous injection, delivered as two 1.5 mL injections, plus 600 mg orally on day 1 and 600 mg orally on day 2. Continuation is 927 mg by subcutaneous injection every six months, or 26 weeks, within a two-week window. The label also requires HIV-1 screening before initiation and before each subsequent injection, using a test approved or cleared by FDA for acute or primary HIV-1 infection. That turns a Yeztugo course into a clinic-managed prevention service, not just a drug shipment.

The product evidence is strong. In PURPOSE 1, a randomized active-controlled trial in cisgender adolescent girls and young women in South Africa and Uganda, Yeztugo recorded zero incident HIV-1 infections at the analyzed endpoint over 1,939 person-years, compared with 16 infections for Truvada over 949 person-years. The label reports a rate ratio of 0.000 with a 95% confidence interval of 0.000 to 0.101 and p less than 0.0001. In PURPOSE 2, conducted among cisgender men, transgender women, transgender men and gender nonbinary individuals at risk through sexual activity with male partners across several countries including the United States, Yeztugo recorded 2 infections over 1,938 person-years versus 9 infections for Truvada over 967 person-years. The reported reduction in risk over Truvada was 89%, with a rate ratio of 0.111 and p of 0.00245.

That is the clinical foundation for a premium course. Yeztugo reduces the adherence burden from daily oral PrEP to twice-yearly injections after initiation. It also creates a long interval in which missed daily pills are not the main failure mode. For clinics serving patients who struggle with daily adherence, stigma, housing instability, disclosure concerns or refill gaps, that convenience can be medically meaningful. A payer can see the evidence and understand the claim: fewer dosing events, strong trial results, potentially better real-world continuity for some patients, and the possibility of avoiding infections whose lifetime treatment costs are large.

But the same label explains why the payer must treat the course as a managed contract. Yeztugo carries a boxed warning about the risk of drug resistance when used for PrEP in undiagnosed HIV-1 infection. The label says drug-resistant HIV-1 variants have been identified in individuals with undiagnosed infection and that Yeztugo should not be initiated unless negative infection status is confirmed. It warns that residual lenacapavir concentrations may remain in the body for up to 12 months or longer after the last subcutaneous dose, that alternative PrEP should be considered within 28 weeks after discontinuation for individuals still at risk, and that non-adherence to every-six-month dosing or missed doses could lead to HIV acquisition and resistance. The course is valuable because it is long acting; it is risky for the same reason if testing, follow-up or transition planning fails.

The price question therefore has two layers. The first layer is whether the list or net price of a six-month injection course can be justified against oral PrEP substitutes. Public reporting around the US launch cited an annual Yeztugo list price of $28,218. That number is a proxy, not the net price any one payer will pay after rebates, discounts, 340B transactions, patient assistance and plan design. Even as a proxy, it frames the payer negotiation: the course is not merely competing against branded convenience. It competes against generic daily PrEP that can be bought far more cheaply, against branded Descovy in selected populations, against ViiV Healthcare's long-acting Apretude, and against the public health cost of untreated or newly acquired HIV.

The second layer is whether the course can lower system cost or improve outcome enough for payers to bear the upfront spend. The clinical trials prove efficacy under trial conditions and support the dosing model. They do not prove every payer's budget impact. A payer still needs local incidence, adherence, discontinuation, testing cost, provider administration cost, patient mix, expected displacement of oral PrEP, and the value assigned to avoided infections. If Yeztugo is used mostly in people already well served by low-cost oral PrEP, the premium is harder to defend. If it reaches people who are at high risk and poorly served by daily tablets, the value case improves materially. The public record supports the second possibility, but it does not publish enough payer-specific uptake and adherence metrics to settle it.

Gilead's own filings make the payer squeeze visible. Gross-to-net deductions of 41% of gross product sales in 2025 are not a footnote; they are a central part of the business model. The company records product sales net of estimated rebates, chargebacks, patient co-pay assistance, early-payment discounts, distributor fees, sales returns and related deductions. The 2025 increase in gross-to-net deductions was attributed mainly to the US Medicare Part D program redesign. In Q1 2026, Gilead described several policy pressures: Medicare price negotiation under the Inflation Reduction Act, inflation-based rebates, redesigned Part D manufacturer discounts, possible effects on Medicaid rebate obligations and 340B ceiling prices, state affordability measures, and cost-containment moves by public programs.

The IRA issue is particularly important for the patent clock. Gilead's Q1 2026 filing says that in January 2026 the Department of Health and Human Services selected Biktarvy for maximum fair price determination effective beginning in 2028, and that Gilead anticipates the negotiated Medicare price will be substantially lower than the price it currently charges in Medicare. Whatever the final mechanics, the public message is plain: a blockbuster course can face government price compression before patent expiry. That changes how the clock works. Patent protection may delay generic entry, but it does not guarantee unchanged realized price throughout the protected period.

Gilead also disclosed an agreement with the US administration in December 2025 related to tariff exclusion, additional US manufacturing investment, most-favored-nation pricing in Medicaid for selected existing products through a government model, most-favored-nation pricing for future launched products in the US market, a new direct-to-patient price for Epclusa, and a return of a portion of increased international revenues if the US government succeeds in increasing drug prices abroad. This disclosure is not just political background. It shows how a treatment course is now negotiated across patent, manufacturing location, Medicaid price, direct-to-patient pricing, and international reference-price pressure. A payer evaluating Gilead is not only evaluating evidence. It is watching a policy negotiation around the right price of protected medicines.

The patent record provides the other half of the argument. In the 2025 Form 10-K, Gilead lists Biktarvy's US patent expiration as 2036 and EU patent expiration as 2033. It also says the company reached settlement agreements in October 2025 with Lupin, Cipla and Laurus Labs related to abbreviated new drug applications for generic Biktarvy, and that no generic US entry is expected before April 1, 2036 for the adult tablet strength, subject to standard acceleration provisions. For pediatric strength, the expected date is November 19, 2035 if pediatric exclusivity is granted, or May 19, 2035 if not. Descovy is listed with US expiration in 2031 and EU expiration in 2027. Yeztugo and Sunlenca are listed with US and EU patent expiration in 2037.

Those dates appear long, but the clock is already moving. Descovy's EU expiration is close. Biktarvy's Medicare price pressure begins before its expected US generic entry. Genvoya has a 2029 US date in the patent table, with a later non-exclusive license date for one generic settlement related to certain patents beginning August 6, 2032 or earlier in certain circumstances. Trodelvy has US patent expiration in 2028 and regulatory exclusivity in the US expiring in 2032. Tecartus has a 2027 US date. Patent protection does not arrive all at once or vanish all at once; it expires product by product, jurisdiction by jurisdiction, with settlements, regulatory exclusivities and litigation determining the practical slope.

For Gilead, that means Yeztugo has to do more than launch. It must grow fast enough to help defend the HIV franchise as older products face price and substitution pressure. It must avoid being boxed into a narrow niche by payers who prefer cheaper daily oral options. It must be manufactured and administered reliably enough that clinic operations do not become a bottleneck. It must avoid safety or resistance concerns large enough to narrow use. It must also coexist with Biktarvy, Descovy and future HIV combinations without simply cannibalizing more profitable courses. The first reported quarter is encouraging but small beside the base: $166 million of Yeztugo sales in Q1 2026 compared with $3.361 billion for Biktarvy and $807 million for Descovy.

Manufacturing resilience is part of the same economics. Gilead's annual report says raw materials are generally available from multiple sources and normally available in quantities adequate to meet business needs. It also says the company attempts to manage supply-chain risks through inventory management, relationship management and evaluation of alternative sources when feasible. That sounds reassuring until it is paired with the risk language. The filing says suppliers of key components and materials must be named in new drug or biologics applications or marketing authorization applications, and significant delays can occur if a new supplier must be qualified. It says Gilead depends on contract manufacturing organizations, contract testing laboratories and corporate partners for the majority of active pharmaceutical ingredients and drug products, and that some products and materials are manufactured or tested by only one supplier or at only one facility.

This matters to payers because a high-priced course is not valuable if it is unavailable or interrupted. For small-molecule HIV tablets, the operational question is not the same as individualized cell therapy, but it is still material: API supply, packaging, testing, quality release, and regulatory compliance affect continuity. For long-acting injections, inventory and clinic scheduling compound the issue. If a patient must receive an injection every six months and alternative PrEP should be considered within a specified window after discontinuation, then supply and appointment reliability become part of the product's economic promise. The course asks the system to trust that Gilead can keep the medicine available and the logistics predictable.

Gilead's manufacturing footprint also explains why policy pressure can turn into operational pressure. The 2025 Form 10-K lists manufacturing and related facilities in Foster City, La Verne, Oceanside, El Segundo, Santa Monica, Frederick, Cork and Dublin, with different functions across process development, clinical manufacturing, commercial manufacturing, quality control, packaging, labeling and distribution. The Q1 2026 filing discusses significant multi-year US manufacturing and research investments, including an initiative to invest $32 billion in the United States through 2030, while warning that construction delays, cost inflation, permitting, skilled-labor availability, process validation and inspections could affect returns. A payer does not need to fund the factory directly, but the factory is embedded in the price story.

Customer dependence and switching costs cut both ways. On one hand, Gilead's HIV business benefits from clinical familiarity, prescriber confidence, patient stability and the caution clinicians use when changing successful antiretroviral regimens. A well-tolerated HIV treatment course with durable viral suppression is not switched casually. That supports Biktarvy's scale and helps explain why patients move from older Gilead products to newer Gilead products rather than leaving the franchise altogether. On the other hand, payers have tools: formularies, prior authorization, step edits, rebate negotiations, public-program exclusions, inventory management and pressure toward generics. The Florida ADAP disclosure shows that even a leading HIV medicine can lose or face restricted access in a budget-constrained program.

The wholesale channel adds another layer of evidence. About 60% of Gilead's accounts receivable balance at March 31, 2026 related to the three large wholesalers and their specialty distributor affiliates. Historically, approximately 90% of US gross product sales have gone through the same three wholesalers and specialty affiliates. That does not mean those wholesalers decide the clinical value of the course. It means reported sales can move with channel inventory as well as patient demand. Gilead explicitly warns that wholesaler, sub-wholesaler, retail and specialty pharmacy inventory patterns can cause quarterly revenue to diverge from prescription demand. The Q1 2026 filing refers to unfavorable inventory dynamics in HIV and notes that non-retail purchasing patterns can be less predictable.

Competitors and substitutes are not theoretical. In PrEP, generic oral emtricitabine/tenofovir disoproxil fumarate is the baseline substitute for many patients. Descovy is a branded oral prevention option, but it does not erase generic pressure. Apretude, ViiV Healthcare's long-acting cabotegravir injection, gives payers and clinics a long-acting alternative. Gilead's own Sunlenca treats heavily treatment-experienced patients with multidrug-resistant HIV, while Yeztugo applies lenacapavir to prevention. The label's strong trial results help Yeztugo stand out, but payer decisions will compare the price of the six-month course against available alternatives, expected adherence, local infection risk, and the cost of clinic administration and testing.

In treatment, Biktarvy competes with other branded antiretroviral regimens and eventual generics. Gilead's annual report says its products compete based on efficacy, safety, tolerability, physician acceptance, ease of patient compliance, ease of use, price, insurance and other reimbursement coverage, distribution and marketing. This is the right list because it mixes medical and commercial factors. A course can be clinically strong and still lose preferred status if a payer can obtain adequate outcomes more cheaply. A cheaper substitute can be economically attractive but clinically inappropriate for some patients. Gilead's margin sits in the space between those two truths.

Oncology is a secondary but important comparison. Trodelvy sales rose to $1.397 billion in 2025, but the 2025 Form 10-K notes the increase was partly offset by the withdrawal of an indication in bladder cancer treatment. The same annual report records major impairment history related to Trodelvy in non-small cell lung cancer in 2024, after a Phase 3 study did not meet its primary endpoint and after Gilead discontinued a second-line metastatic NSCLC development program. In 2025, the company recorded a $590 million impairment related to bulevirtide after competitive clinical data changed assumptions about a more competitive market outside the EU. These are not HIV facts, but they reinforce the treatment-course argument: even after large investment, expected value can fall quickly when clinical evidence, regulator expectations or rival treatments shift.

Cell therapy shows the most operationally complex course. Yescarta and Tecartus are not ordinary pharmacy products; they require patient cell collection, chain-of-identity and chain-of-custody control, specialized manufacturing, certified sites, reimbursement alignment and hospital willingness. Gilead's Q1 2026 filing says the Kite Konnect platform is critical to maintaining chain of identity and chain of custody for cell therapies. The company also warns that reimbursement structures do not always adequately reimburse innovative therapies, and that even a higher Medicare inpatient diagnosis-related group may not be sufficient for some hospitals' cost of care. The lesson carries back to HIV: the more a course depends on operations beyond a tablet, the more access is shaped by systems, not just labels.

Unofficial and market signals point in the same direction, but they should be weighted below filings and labels. Public reporting after Yeztugo's approval described the US annual list price as $28,218. That is useful as a list-price proxy because payers negotiate from a visible starting point, but it cannot reveal net price after rebates or discounts. Press reports also indicated payer resistance. Coverage noted that CVS Health's pharmacy benefit manager declined to cover Yeztugo on some formularies in 2026, while other reporting discussed concerns about how a high list price would affect public health access. These signals suggest the launch met immediate reimbursement friction. They do not prove final coverage, net price, patient uptake or long-term budget impact.

The strongest conclusion from those signals is not that Yeztugo will fail. It is that Gilead's evidence advantage must be converted into access architecture quickly. A twice-yearly PrEP course has a clear clinical proposition. Payers can still ask why the highest-risk patients will receive it, whether clinics can meet testing and scheduling obligations, how missed injections will be managed, whether cheaper options were tried or ruled out, and how much the medicine reduces infections in their population. Those are fair economic questions. Gilead's commercial task is to show that the course is not a premium convenience product for the already well served, but a prevention infrastructure for people whose risk and adherence barriers make daily oral PrEP less effective.

Network-resource evidence should be bounded. Public DNS lookups for gilead.com resolve the apex domain to 40.70.27.35, and ARIN RDAP attributes the relevant 40.64.0.0 to 40.71.255.255 range to Microsoft Corporation. The www.gilead.com host resolves through Cloudflare CDN addresses 104.16.86.81 and 104.16.87.81. The domain's MX records point to Proofpoint-hosted mail exchangers, and TXT records show a broad enterprise SaaS surface including Microsoft, Zoom, DocuSign, Salesforce Marketing Cloud, Smartsheet, Atlassian, Notion, Adobe identity and other verification strings. These records prove that the public web and mail surface relies on large cloud, CDN, email-security and SaaS providers. They do not prove drug safety, manufacturing continuity, payer adoption, clinical value, revenue quality or patient access.

That boundary is important for BTW readers because Gilead is not a cloud company. Digital dependency matters as operational context: investor relations, product information, safety reporting pathways, patient support, field operations and enterprise communications depend on resilient technology. The records are also relevant to data locality questions because a global health company handles sensitive health, clinical, employee and partner information across jurisdictions. But DNS evidence should not be inflated into a conclusion about regulated manufacturing or clinical trial integrity. Those are governed by FDA, EMA, GxP processes, inspections, vendor controls and the company's own disclosures, not by whether the public website sits behind Cloudflare.

Three pricing proxies are visible enough to support the argument. The first is realized revenue and product gross margin: $28.915 billion of 2025 product sales, 78.4% gross margin, and $6.946 billion of Q1 2026 product sales at a 79.2% product gross margin. That shows high-margin commercial durability. The second is gross-to-net pressure: 41% of gross product sales in 2025 disappeared into deductions, including rebates and chargebacks, and Gilead links the increase to Medicare Part D redesign. That shows the gap between list-price strategy and realized economics. The third is the launch price and substitute comparison for Yeztugo: public reporting of a $28,218 annual list price must be weighed against generic oral PrEP, branded Descovy, Apretude and public-health budgets. A fourth proxy is public-program behavior: Florida ADAP's Biktarvy removal and Descovy restrictions show that institutional buyers can ration access when budgets tighten.

The fixed and variable cost base is also clear enough to map, though not by product. Gilead says it does not track total R&D expenses by product candidate, therapeutic area or development phase. At company level, 2025 cost of goods sold was $6.234 billion, research and development expense was $5.799 billion, selling, general and administrative expense was $5.774 billion, and interest expense was $1.024 billion. Q1 2026 R&D was $1.372 billion and SG&A was $1.451 billion. Fixed and semi-fixed costs include research staff, clinical studies, facilities, commercial teams, regulatory work, legal operations, manufacturing facilities, quality systems, and debt service. Variable or volume-linked costs include manufacturing inputs, contract services, distribution fees, rebates, chargebacks, co-pay assistance, royalties, and product-specific promotional spend.

The supplier and upstream picture is mixed. Gilead has internal facilities and a broad commercial footprint, but it also depends materially on external manufacturers, testing laboratories, research contractors, distributors, logistics providers and corporate partners. For some products, only one supplier or facility may manufacture or test a needed material. For cell therapies, collection centers, shippers, couriers and hospitals are part of the actual delivery system. For HIV tablets and injections, the course appears simpler to the patient, but supplier qualification, active ingredient supply, sterile manufacturing for injectables, packaging, temperature and storage rules, and regulatory compliance remain part of the paid unit. A payer does not price each of those components separately, yet the price of the course embeds them.

The payer lanes differ enough that one national answer would be misleading. A commercial pharmacy-benefit manager can prefer a lower net-cost oral product, require prior authorization for a new long-acting option, or use formulary placement to demand rebates. Medicare Part D plans are shaped by benefit redesign, manufacturer discounts, catastrophic-phase obligations and eventual negotiated prices. Medicaid and 340B create separate rebate and ceiling-price effects. ADAPs can be more exposed to state grant cycles and budget politics, which is why the Florida disclosure matters. Correctional systems and Veterans Affairs facilities are different still: they buy for populations where continuity, security, staffing and procurement rules can determine whether a six-month visit schedule is feasible. The course is medically the same molecule, but the economic buyer is not the same buyer.

That fragmentation makes launch math difficult. If Yeztugo earns rapid coverage in commercial plans but faces restrictions in public programs serving high-risk patients, the product can generate revenue while missing part of its public-health rationale. If it is prioritized for people with documented adherence barriers, unstable housing, confidentiality concerns or repeated oral-PrEP discontinuation, then the course may look expensive on a drug-only comparison but more efficient on an avoided-infection comparison. If it is used broadly for patients already doing well on low-cost oral therapy, the payer argument weakens. The public record does not yet disclose this segmentation. Q1 2026 sales show adoption; they do not show whether adoption is concentrated in the patients for whom long-acting prevention has the highest incremental value.

Gilead's older franchises show why this distinction matters. Veklury was a major COVID-19 hospital antiviral during the pandemic, but 2025 sales fell 49% to $911 million as COVID-19-related hospitalizations declined. That was not primarily a patent event. It was a demand event. The public value of a treatment course changed because the clinical burden it addressed changed. Sofosbuvir/velpatasvir sales fell 20% in 2025, and Gilead said liver-disease results were partly offset by lower average realized price, most notably for chronic hepatitis C virus products, including Medicare Part D redesign effects. In oncology, cell therapy sales fell 7% in 2025 under competitive headwinds. These examples show that patent duration is only one clock. Epidemiology, hospitalization rates, curative-treatment pools, rival regimens and payer benefit design can move faster.

The hepatitis C comparison is especially useful because Gilead has lived through a different version of the same access debate. A high-value curative course can be medically transformative and still face payer restrictions when budgets encounter a large eligible population. Over time, treated prevalence, competition and net-price pressure can shrink the revenue base even when the medicine remains useful. HIV treatment is more durable because it is chronic rather than curative, but prevention is closer to a population-budget decision: the buyer must decide how much to spend before infection occurs. That makes Yeztugo's value highly dependent on targeting, adherence and incidence. A prevention course creates value by avoiding a future event. The event is visible in epidemiology, not in the pill bottle or injection kit.

Acquisition payback adds another clock. Gilead's 2025 and Q1 2026 filings show a company still buying future courses with large upfront commitments. The 2025 annual report described a February 2026 agreement to acquire Arcellx for an estimated $7.0 billion excluding pre-existing holdings, tied to anito-cel, an investigational BCMA-directed CAR T-cell therapy. The Q1 2026 filing says that deal closed in April 2026 for approximately $7.1 billion in cash consideration. It also describes a pending Tubulis acquisition for about $3.2 billion upfront plus up to $1.9 billion in contingent milestone payments, and an Ouro Medicines agreement for about $1.7 billion upfront plus up to $500 million in contingent milestones. These transactions are not HIV revenue, but they show how today's protected courses fund tomorrow's access arguments.

The economics of those deals depend on future courses achieving their own payer contracts. A CAR T-cell therapy must clear clinical evidence, manufacturing scalability, site certification, hospital economics and payer reimbursement. An antibody-drug conjugate must prove enough benefit in crowded oncology indications to command access. An autoimmune T-cell engager would face its own benefit-risk and budget tests. If those future courses disappoint, Gilead's income statement can absorb impairments, as it has before, but the strategic burden falls back on the HIV base. The more policy compresses Biktarvy or Descovy, the more each new course must replace not just scientific optionality but cash-flow durability.

This is why gross margin should not be read as pure pricing power. A 78% to 79% product gross margin is high, but it sits above a large and recurring commercial and research apparatus. Gilead spent $5.774 billion on SG&A in 2025 and $1.451 billion in Q1 2026 alone. Those amounts include selling, marketing, administrative work, compliance, legal and patient-support infrastructure. The company spent $5.799 billion on R&D in 2025 and $1.372 billion in Q1 2026. It had $24.937 billion of total debt net at year-end 2025 and $22.174 billion at March 31, 2026, including future royalty liabilities. A payer negotiating a course does not pay those line items directly, but the company prices in a way that must cover scientific failure, commercial reach, debt service, manufacturing resilience and shareholder expectations.

The article's thesis also depends on switching costs being real but not absolute. In HIV treatment, once a patient is virologically suppressed and tolerating therapy, changing regimens can create clinical and behavioral risk. That protects incumbents. Yet payers can still shape new starts, switches from older regimens, prior authorization requirements and copay burden. In PrEP, switching costs may be lower for some patients because prevention is elective and adherence-dependent, but the stakes of interruption are high for those at ongoing risk. A missed daily pill and a missed six-month injection are different failures. A payer must ask whether a long interval reduces the most common failure or creates a more dangerous discontinuation tail. The label acknowledges that tail through its residual-concentration and resistance language.

The strongest case for Gilead is therefore not that its prices are simply acceptable. It is that the company can often pair high prices with evidence and operations that make a course hard to replace for the right patient. Biktarvy's scale indicates clinical and commercial preference. Descovy's growth indicates prevention demand and pricing resilience despite substitutes. Yeztugo's trial results and dosing schedule give it a differentiated prevention claim. But each advantage is conditional. Biktarvy must absorb negotiated Medicare pricing before generic entry. Descovy must withstand generic oral PrEP and policy restrictions. Yeztugo must prove that six-month dosing converts trial efficacy into better real-world prevention for populations not well served by daily pills. Oncology and cell therapy assets must prove that complex courses can overcome manufacturing and reimbursement friction.

There is also a reputational access risk. Gilead's filings repeatedly note public scrutiny around pricing, global supply, distribution, allocation and intellectual property. That scrutiny is not external noise. In HIV, the company sells medicines linked to public-health goals and prevention equity. A high list price for a prevention injection can be defensible if the access model reaches those most likely to benefit; it becomes politically vulnerable if it appears to reserve the newest evidence for the best-covered patients. Gilead can partially answer through assistance programs, voluntary licensing, discounts, public-program arrangements and targeted contracting. The public evidence available here does not show enough of those details to judge execution.

The most useful monitoring frame is a simple sequence. First, watch whether Yeztugo coverage broadens or narrows across commercial plans, Medicaid, ADAPs and large public buyers. Second, watch whether Biktarvy's negotiated price and rebate spillovers reduce the HIV franchise's effective cash flow before 2036. Third, watch whether Descovy's PrEP growth holds when payers compare it with oral generics and long-acting options. Fourth, watch whether manufacturing investments and supplier diversification reduce the risk language that Gilead itself identifies. Fifth, watch whether new oncology and inflammation assets convert acquired cost into reimbursed courses rather than impairment charges. The argument is not static; it is a moving test of evidence, access and time.

The reason to keep the frame disciplined is that Gilead can look stronger or weaker depending on which metric is isolated. Product sales make the company look robust. Gross-to-net deductions make the same sales look contested. Patent dates make the franchise look protected. Medicare negotiation and ADAP restrictions make that protection look porous. The label makes Yeztugo look clinically differentiated. List-price reporting and early coverage friction make it look commercially exposed. None of these readings is sufficient alone. Together they describe a company whose advantage is real but continuously repriced by the institutions that decide whether a course reaches the patient.

Regulation and geopolitics add risk beyond normal competition. Gilead's Q1 2026 filing discusses the Inflation Reduction Act, the 340B program, Medicaid and Affordable Care Act changes, most-favored-nation pricing proposals, tariffs on patented pharmaceutical products and associated ingredients, state drug-pricing legislation, EU reimbursement reviews, and potential funding changes for domestic and international HIV treatment and prevention programs. It also discusses the BIOSECURE Act and other laws that may affect biotechnology equipment, services, goods and materials. The broad message is that the treatment course is no longer protected only by patents and evidence. It is exposed to industrial policy, federal procurement design, state affordability boards, trade rules and program funding.

What would change the judgement? First, net-price transparency by product would materially improve the analysis. Public filings show aggregate gross-to-net deductions and product revenue, but they do not show net realized price for Biktarvy, Descovy or Yeztugo by payer channel. Second, real-world Yeztugo persistence, missed-injection rates, discontinuation transitions, resistance outcomes and population-level infection reductions would determine whether the label's trial advantage becomes payer value. Third, state ADAP and Medicaid formulary decisions over the next several cycles would show whether Florida was an outlier or an early warning. Fourth, any change in Biktarvy's Medicare negotiated price, and any spillover into Medicaid or 340B, would directly affect the franchise's protected cash flow before 2036.

Fifth, manufacturing evidence would matter. The public record identifies facilities, supplier risks and planned US investment, but it does not provide product-by-product supply resilience metrics. For a long-acting prevention course, payers and clinics would benefit from clearer public evidence on fill rates, inventory continuity, site readiness, appointment adherence support and contingency plans. Sixth, competitor data could change the margin. If Apretude, oral generics or future long-acting alternatives deliver similar access results at lower net cost, the premium for Yeztugo narrows. If Yeztugo demonstrably reaches high-risk people who were not successfully using oral PrEP, the premium becomes easier to defend.

Public evidence

The evidence supports the core thesis with important limits. Gilead's treatment courses are expensive because they combine strong clinical evidence, protected intellectual property, regulated manufacturing, global distribution, professional prescribing trust and payer access work. The public record also shows that those same courses are under constant pressure from gross-to-net deductions, Medicare redesign, state public-program budgets, generic applicants, rival therapies and policy bargaining. Biktarvy remains a powerful protected franchise, but its price is already subject to policy negotiation before the expected 2036 US generic entry date. Descovy is growing but faces a nearer EU clock and prevention substitutes. Yeztugo has the strongest new product evidence in the public record, but its course only just began to show revenue in Q1 2026.

The public record suggests that Gilead's current economics are defensible, not effortless. The company has real evidence, real scale and real manufacturing capacity. It also has a visible payer problem: a high-value course must keep proving that it reaches the right patients at a net price public and private payers can absorb. The thesis remains unproven without product-level net prices, channel-specific coverage decisions, real-world Yeztugo persistence and infection outcomes, and the final effect of Medicare negotiation on Biktarvy. Until those metrics are visible, the best reading is conditional: Gilead's treatment course can outrun the patent clock only if its evidence and access model move faster than payer compression.